|
Vevoctadekin Clinical Trials
1 actively recruiting trial across 1 location
Also known as: Engineered IL-18 Variant ST-067, Engineered Interleukin-18 Variant ST-067, ST 067, ST-067, ST067, Variant ST-067
Seattle, Washington1 trial
ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma
Fred Hutch/University of Washington Cancer Consortium
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.